Skip to main content

One‐year results of growth hormone treatment of short stature in Prader—Willi syndrome

Buy Article:

$43.00 plus tax (Refund Policy)

At least part of the short stature in Prader—Willi syndrome may be explained by a decreased growth hormone (GH) secretory capacity, which occurs in most patients. To study the effects of exogenous GH on growth and body composition, 17 prepubertal children with Prader—Willi syndrome, with a short projected final height, were randomized to a control group (n = 9) or a treatment group (n = 8). Children in the treatment group received GH (0.15 IU/kg/day s.c.) for 1 year. One patient in the treatment group developed pseudotumor cerebri, which resolved after discontinuation of GH; this patient was omitted from further analysis. After 1 year, height velocity in the GH‐treated group was significantly increased (+5.5 SD) compared with reference values for normal healthy children, whereas there was a decrease in the control group (–2.3 SD). The difference in height velocity between the treated and control groups was significant (p = 0.0012). Concentrations of both insulin‐like growth factor I (IGF‐I) and IGF‐binding protein‐3 increased significantly in the GH‐treated group (p < 0.008). A gain in height was noted for chronological age (+1.07 SD) after 1 year of GH treatment. Height gain (+1.02 SD) remained unchanged when analysed in relation to bone age. No differences between the groups were found for parameters of weight and body composition. In conclusion, although GH appears to have beneficial effects on height, long‐term studies are necessary before recommendations can be made concerning GH treatment in children with Prader—Willi syndrome. □ Body composition, growth, growth hormone treatment, height velocity, insulin‐like growth factor‐binding protein‐3, insulin‐like growth factor I, Prader—Willi syndrome, side‐effects
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Short Communication

Publication date: 1997-11-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more